Friday, March 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

VSV Vaccine Early Immune Response Findings May Help Rapid Countermeasure Development

by Global Biodefense Staff
September 8, 2017
Ebola Virus Sample from Mali

Ebola virus (green) on a cell in culture. The virus was isolated in November 2014 from patient blood samples obtained in Mali. Credit: NIAID.

Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV) is one of the most promising candidates against the Ebola virus. In phase I of the clinical trial in 2016, it proved to be a safe and effective vaccine and is expected to be approved this year by the U.S. Food and Drug Administration.

Researchers at the Heinrich Pette Institute and the University Medical Centre Hamburg-Eppendorf (UKE) this week published a study on early responses of the innate immune system in humans who have been vaccinated with vesicular stomatitis virus (VSV), which when weakened and genetically modified, expresses a glycoprotein of the Ebola virus.

For the study, blood samples were analyzed for changes in cytokine levels, innate immune cell subsets, and gene expression. The team identified a signature of five early immune markers correlating with the indicative antibody titer four weeks after vaccination. Among these biomarkers was IP-10 (interferon-gamma induced protein 10). The identification of IP-10 marks the first time  a soluble immune marker could successfully be identified as “activated” shortly after vaccination, and correlates with the degree of subsequent antibody response regardless of other early immune markers.

The finding could assist future efforts to increase the efficacy of the VSV vaccine for Ebola or other emerging viruses (such as Zika) by manipulating IP-10.

The development of rVSV-ZEBOV was supported by the WHO-led VEBCON. The German Centre for Infection Research supported the preparation of the studies at the UKE in Hamburg and in Gabon and provided the initial funding, the Federal Ministry of Health (BMG) and the British Wellcome Trust provided the funds to prepare and conduct the clinical trial. The Canadian health authorities donated the vaccine candidate to the WHO, which then made it available for these trials.

Read more: Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV.

Tags: EbolaVaccines

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC